The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Grasustek pegfilgrastim Biosimilar | Juta Pharma GmbH | 🇪🇺 EU 2019-06-20 | Order → | |
| Talzenna talazoparib | Pfizer Europe MA EEIG | Breast Neoplasms | 🇪🇺 EU 2019-06-20 | Order → |
| Trecondi treosulfan | medac Gesellschaft für klinische Spezialpräparate mbH | Hematopoietic Stem Cell Transplantation | 🇪🇺 EU 2019-06-20 | Order → |
| Sixmo buprenorphine Additional monitoring | L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A. | Opioid-Related Disorders | 🇪🇺 EU 2019-06-19 | Order → |
| Temybric Ellipta fluticasone furoate;umeclidinium;vilanterol Additional monitoring | GlaxoSmithKline Trading Services Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2019-06-12 | Order → |
| Zynteglo betibeglogene autotemcel PRIMEATMPConditional | bluebird bio (Netherlands) B.V. | beta-Thalassemia | 🇪🇺 EU 2019-05-29 | Order → |
| Lorviqua lorlatinib | Pfizer Europe MA EEIG | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2019-05-06 | Order → |
| Pazenir paclitaxel Generic | ratiopharm GmbH | Breast Neoplasms | 🇪🇺 EU 2019-05-06 | Order → |
| Palynziq pegvaliase Orphan | BioMarin International Limited | Phenylketonurias | 🇪🇺 EU 2019-05-03 | Order → |
| Waylivra volanesorsen OrphanConditionalAdditional monitoring | Akcea Therapeutics Ireland Limited | Hyperlipoproteinemia Type I | 🇪🇺 EU 2019-05-03 | Order → |
| Dectova zanamivir Exceptional circumstancesAdditional monitoring | GlaxoSmithKline Trading Services Limited | Influenza, Human | 🇪🇺 EU 2019-04-26 | Order → |
| Ondexxya andexanet alfa ConditionalAdditional monitoring | AstraZeneca AB | Drug-Related Side Effects and Adverse Reactions | 🇪🇺 EU 2019-04-26 | Order → |
| Skyrizi risankizumab | AbbVie Deutschland GmbH & Co. KG | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease | 🇪🇺 EU 2019-04-26 | Order → |
| Zynquista sotagliflozin Additional monitoring | Guidehouse Germany GmbH | Diabetes Mellitus, Type 1 | 🇪🇺 EU 2019-04-26 | Order → |
| Idacio adalimumab Biosimilar | Fresenius Kabi Deutschland GmbH | Arthritis, Rheumatoid; Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing; Uveitis; Hidradenitis Suppurativa; Colitis, Ulcerative; Crohn Disease; Arthriti | 🇪🇺 EU 2019-04-02 | Order → |
| Kromeya adalimumab BiosimilarAdditional monitoring | Fresenius Kabi Deutschland GmbH | Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid; Psoriasis; Arthritis, Psoriatic; Spondylitis, Ankylosing; Uveitis; Colitis, Ulcerative; Crohn Disease | 🇪🇺 EU 2019-04-02 | Order → |
| Vizimpro dacomitinib | Pfizer Europe MA EEIG | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2019-04-02 | Order → |
| Ajovy fremanezumab | Teva GmbH | Migraine Disorders | 🇪🇺 EU 2019-03-28 | Order → |
| Febuxostat Krka febuxostat Generic | KRKA tovarna zdravil d.d. Novo mesto | Hyperuricemia; Gout | 🇪🇺 EU 2019-03-28 | Order → |
| Atazanavir Krka atazanavir Generic | KRKA tovarna zdravil d.d. Novo mesto | HIV Infections | 🇪🇺 EU 2019-03-25 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.